Think of Verquvo as a "Niche" Med for Heart Failure

April 2021

You'll hear once-daily vericiguat (Verquvo) is a new add-on for worsening heart failure with reduced ejection fraction (HFrEF).

Vericiguat is the first "soluble guanylate cyclase stimulator" for HFrEF. It relaxes blood vessels through the nitric oxide pathway.

Most evidence is in patients already on triple therapy...an ACEI, ARB, or sacubitril/valsartan (Entresto), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Address New Questions About COVID-19 Vaccines
Education and Training Use Practical Solutions to Manage Resident Burnout
COVID-19 Identify Candidates for COVID-19 Monoclonal Antibodies
Venous Thromboembolism Guide Safe Use of Alteplase for Catheter-Directed Thrombolysis
New Drugs Assess the Role of Remimazolam for Procedural Sedation
Cardiology Know the Latest About Antithrombotics in Heart Valve Replacement
Headache Watch for Elevated BPs From Injectable CGRP Antagonists
Immunizations Verify Correct Use of Meningococcal Vaccines Post-Splenectomy
Heart Failure Think of Verquvo as a "Niche" Med for Heart Failure

Think of Verquvo as a "Niche" Med for Heart Failure

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents